AI Recruitment for Life Sciences


Computational Gastroenterology Can Accelerate Clinical Trials and Improve the Accuracy of Clinical Endpoints

Iterative Scopes is developing powerful, AI-driven computer algorithms to support pharmaceutical companies as they seek to improve the processes for enrolling patients in IBD clinical trials and assessing the drugs’ progress as they move through the clinical development trajectory. 


The Problem


Clinical trials for inflammatory bowel disease (IBD) are expensive, cumbersome and time-consuming, even by current pharmaceutical R&D benchmarks. Manual centralized endoscopy readings are now standard in GI clinical trials, but these are highly dependent on readers’ training and levels of experience and therefore subjective. Manual endoscopy is also used to score disease severity for UC and CD patients, which GI specialists use to determine patient eligibility for clinical trials. 

As a result, misclassification of disease severity is a challenge, often leading to delays in clinical trial timelines.

Automated Disease Severity Scoring 

The Iterative Scopes AI Recruitment service aims to lower the barriers to determine clinical trial eligibility with the goal of accelerating clinical trial timelines. 


The computational software offered through AI Recruitment automates interpretation of colonoscopy images and videos, enabling clinical trial investigators to arrive at standardized MES threshold scores for individual patients, which can accelerate eligible patient enrollment in clinical trials and improve the accuracy and granularity of clinical trial results.

Novel Endpoint Development

Over the past decade, scientists have progressed from an anatomic to a histologic and now a genetic understanding of IBD. However, standard of care disease severity endpoints have remained largely unchanged. 


Iterative Scopes has longer-term ambitions to disrupt the current paradigm for measuring treatment response in IBD clinical trials and clinical care, and is actively building novel predictive models that aim to improve characterization of disease severity and prediction of disease progression and individual therapeutic response. 


While in early development, these have the potential to establish more meaningful endpoints for GI diseases, which may be better predictors of therapeutic responses and disease outcomes. Ultimately, pharmaceutical companies that use these tools will have a strong competitive advantage in an increasingly complex and expensive IBD space.